{
    "nctId": "NCT06174259",
    "briefTitle": "Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients",
    "officialTitle": "Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients: a Prospective Randomized Controlled Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Locally Advanced Breast Cancer, Intermittent Fasting",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 66,
    "primaryOutcomeMeasure": "pathological response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients with stage II or III (cT1cN+ or \u2265T2 any cN, cM0) breast cancer. - Planned to receive standard neoadjuvant chemotherapy.\n* Measurable disease (breast and/or lymph nodes).\n* WHO performance status 0-2.\n* Being overweight (BMI: 25-29.9 kg/m2) or obese (BMI: \u226530 kg/m2).\n* Adequate bone marrow function : white blood cells (WBCs) \u22653.0 x 109/l, neutrophils \u22651.5 x 109/l, platelets \u2265100 x 109/l\n* Adequate liver function: bilirubin \u22641.5 x upper limit of normal (UNL) range, ALAT and/or ASAT \u22642.5 x UNL, Alkaline Phosphatase \u22645 x UNL\n* Adequate renal function: the calculated creatinine clearance should be \u226550 mL/min\n* Patients must be accessible for treatment and follow-up\n\nExclusion Criteria:\n\n* Serious diseases such as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias\n* Diabetes Mellitus.\n* Pregnancy or lactating\n* Any metabolic disorders that may affect gluconeogenesis or adaptation to fasting periods.\n* Previous malignancy.\n* Using weight loss medication.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}